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Laura Dee Sheehan 
Abstract 
Incidence of Clostridium difficile infection, (CDI) in patients receiving antibiotics is 
significant. In 2017, there were approximately 223,900 cases of CDI in hospitalized 
patients alone (Center for Disease Control [CDC], 2017). Despite enhanced infection 
control measures, CDI rates remain prevalent and are associated with increased costs to 
healthcare. An integrative literature review and synthesis was performed. Studies were 
analyzed to delineate if Lactobacillus containing probiotics, when administered 
concurrently with high risk antibiotics, decrease CDI rates for patients in the inpatient 
hospital setting. Additional analysis of probiotic safety and a cost versus benefit analysis 
was researched. The purpose of the review and analysis was to determine the strength of 
evidence for utilization of probiotics. Within this review, the use of probiotics to combat 
incidence of CDI was associated with low risk of adverse effects with probiotic use, and 
moderate effect on reducing CDI rates. Significant cost savings to inpatient facilities is 
also noted. The research findings suggest use of probiotics is associated with improved 
patient outcomes by decreasing incidence of CDI, reduced hospital length of stay, and the 
prevention of the physical and emotional consequences from CDI. A concept map was 
constructed to guide readers through the correlational relationship of a Lactobacillus 
probiotic on CDI rates, institutional cost savings, and adverse events. Despite promising 
findings in safety, cost reduction, and decreased incidence of CDI, due to high 
heterogenicity between studies, details regarding prescribing practices remain unclear. 





 warranted. These findings provide a foundation of knowledge that may be utilized by the 
advanced practice nurse and other healthcare providers. Monitoring for new research that 
emerges, or encouragement for further research to be performed, within the hospital 
setting, is needed. Until then, the data found within this review provides education related 
to the benefits of utilizing probiotics for patients receiving high risk antibiotics with a 
subsequent result of decreased incidence of CDI, decreased mortality related to CDI, and 
long-term cost savings to an institution. Robust clinical trials are needed to validate the 
effectiveness of particular dosages, duration, and species of probiotics. Therefore, 
institutional based prescribing guidelines cannot be formed at this time and prescribing 
should be left to the judgement of the prescribing provider.  
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Clostridium difficile infection (CDI) is a gram-positive bacterium that is highly 
virulent and is the leading cause of hospital acquired antibiotic associated diarrhea (Lau 
& Chamberlain 2016, p. 27). The diagnosis of CDI results in detrimental outcomes as 
increased length of hospital stays, increased risk for systemic infection, and increased risk 
of morbidity. In addition, CDI results in increased costs to institutions due to costs 
accumulated from additional treatment of infection, increased length of hospital stay, and 
additional safety measures to prevent the spread of the infection (personal protective 
gowns and specialized bleach cleaners), which is often not reimbursed by insurance. 
Despite enhanced infection control measures CDI rates remain prevalent in the hospital 
setting affecting on average thirteen per one-thousand patients (Center for Disease 
Control (CDC), 2017).  According to the Cochrane Database, the use of probiotics has 
been studied for its effects on CDI rates for many years (Chaturaka, 2018). This leads to 
the question of the use of  probiotics and can they be efficacious, safe, and cost-effective 
method to combatting hospital acquired CDI.  
To address the inquiry question, this scholarly inquiry project reviewed current 
literature regarding probiotic’s effects on reducing hospital acquired CDI rates. 
Background and rationale of the impact of CDI and the biochemical chemical effects of 
probiotics are explained. The significance of hospital acquired Clostridium difficile in 
terms of mortality rates and cost burdens are highlighted. Purpose and PICOT formed 
question is presented to clearly inform the reader, the intent of this scholarly inquiry 




Background and Rationale 
CDI is an opportunistic gastrointestinal infection that occurs when normal 
intestinal microbiome is disrupted. Symptoms may range from mild diarrhea to severe 
colitis. In severe cases, CDI may result in sepsis, ischemic colon, possible colostomy, 
and/or death. The criteria of mild to severe CDI along with recommended treatment is 
described in Table Al Clinical Definition and Recommended Treatment for Clostridium 
difficile Infection in Adults. Use of antibiotics, advanced age, recent hospitalization, and 
an immunocompromised state of health are the leading precipitating factors to CDI 
(Tilton & Johnson, 2018, p. 280). Risks of developing CDI are further increased for 
patients receiving high risk antibiotics such as: Cefepime, Clindamycin, Piperacillin, 
Ciprofloxacin, Fluoroquinolones, and Vancomycin, due to the increased disruption of 
normal gastrointestinal flora (Tilton & Johnson, 2018, p. 282). Increased incidence of 
CDI in hospitals is due to higher presence of the virulent Clostridium difficile strain in 
hospital settings (CDC, 2017). Research has shown, up to 20-50 % of hospital surfaces 
contain Clostridium difficile spores (McFarland, Ship, Auclair, & Millette, 2018, p. 444). 
The high virulence of CDI is due to the Clostridium difficile spores being resistant to 
hand sanitizer and many typical disinfectant cleaners, requiring handwashing and 
cleaners with bleach to disinfect surfaces (CDC, 2019)  
Health care associated CDI is defined as Clostridium difficile infection diagnosed 
more than 48 hours after hospital admission and/or less than four weeks after discharge 
from a hospital facility (Starn, Harpe, & Cline, 2016, p. 238). CDI has become one of the 




Antibiotic Resistance Threats report, in 2017 there were approximately 223,900 cases of 
CDI (CDC, 2019). 
Clostridium difficile infection results in a financial burden of nearly five billion 
dollars for American hospitals (CDC, 2017). On average, each incident of hospital 
acquired CDI, in the United States, costs between 18,676- 27,408 dollars and this does 
not include quality of life adjustments (Heimann, Aguilar, Mellinghof, & Vehreschild, 
2018, p. 24). Additional costs accrued are due to increased length of hospital stay, 
additional treatment methods (antibiotics, antifungals), need for personal protective 
gowns, specialized bleach cleaning products, and additional room cleaning methods 
(Zhang et al., 2016). CDI is often coded as a healthcare associated infection resulting in 
little to no reimbursement for hospitals that participate in Center for Medicaid Service 
programs (CDC, 2017).  
Mortality rates associated with CDI are high. According to the CDC (2017), one 
out of 11 patients who are 65 years or older die within 30 days of diagnosis of CDI 
(CDC, 2017). Mortality rate after 90 days is further increased to 22% (McFarland et al., 
2018, p. 444). For those who do survive, the infection may leave an impact and burden on 
one’s physical, mental, and emotional health.  In a qualitative study by Guillemin et al. 
(2014), the authors conclude that CDI was a traumatic and frightening experience for 
patients. One patient describes the fatigue she experienced topped with the 
embarrassment of being in an isolation room, she then describes when she returned home, 
she could not return to work for a few weeks due to the increased frequency of her bowel 




the study may encourage providers to take extra precautions to prevent occurrence of the 
infection (Guillemin et al., 2014, p. 97). 
Despite the CDC’s initiative to promote antibiotic stewardship through decreased 
prescribing practices of antibiotic and increased education of modified contact 
precautions in the inpatient hospital setting, infection rates remain significant (McFarland 
et al., 2018, p. 444). Use of probiotics to support gastrointestinal health has been 
speculated for quite some time (Chaturaka, 2018). In a meta-analysis performed by 
McFarland et al. (2018), authors note that probiotics helped to restore the intestinal 
microbiome and reduced bioavailability which resulted in decreased Clostridium difficile 
growth. Additionally, probiotics may neutralize toxins released by Clostridium difficile 
resulting in reduced inflammation in the gastrointestinal tract (McFarland et al., 2018, p. 
444). The role probiotics play in decreasing bioavailability and in turn decreasing 
Clostridium difficile proliferation seems plausible (Lewis, Lundberg, Tharp, & Runnels, 
2017, p. 849). However, due to lack of sufficient research, prescriber use of probiotics as 
a prophylactic measure to decrease the incidence of CDI remains variable.  
Purpose and PICOT Question 
The purpose of the integrative literature review was to analyze studies in which 
probiotics are used as a measure to prevent CDI, analyze the safety of probiotic 
formularies, and determine costs savings related to probiotic implementation. Therefore, 
the aim of the review is to determine whether probiotics are safe and beneficial in the 
prevention of Clostridium difficile for patients who are receiving antibiotic therapy most 
prone to causing CDI. Concurrently, the secondary aim was to determine if there was 




 To effectively perform a review of literature and explore the clinical inquiry, a 
PICOT question was formed. PICOT is a format used to develop a clinical question that 
guides a review of literature. PICOT is an acronym for the following elements: P- 
population of interest, I- intervention described, C-comparison for the intervention, O- 
outcomes to be measured, and T- timeline (Gray, Grove, & Sutherland, 2017, p. 459). 
The PICOT question developed was: 
“For adult patients in the hospital setting who receive high risk antibiotics associated with 
the development of CDI, (Cefepime, Piperacillin, Ciprofloxacin, Fluoroquinolones, 
Vancomycin, Clindamycin, and Cephalosporin); is the practice of prophylactically 
administering a Lactobacillus containing probiotic concurrently with a course of 
antibiotic treatment compared to no probiotic intervention, a efficacious, safe, and cost-
effective method to reduce rates of hospital acquired Clostridium difficile infection?” 
Method Used for the Inquiry 
Systematic and exhaustive search methods were conducted from January 2019- 
November 2019. Six research databases were utilized, including: CINAHL, PubMed, 
Cochrane, OVID, EBSCO host, and Google Scholar. Keywords and search terms utilized 
were: prophylactic probiotic, Clostridium difficile, antibiotics, patient experience, 
probiotics, economic burden, infection reduction, cost analysis, and cost saving. Table 
A1. Database Search, delineates the dates of searches, database used, keywords utilized, 
and number of hits obtained. All databases that were used were filtered to articles less 
than ten years old, printed in English, and had human subjects. 
Purpose of the review of literature was to obtain systematic reviews, meta-




question. Special attention was made to find studies that examined a probiotic 
intervention against a placebo or no intervention, probiotics administered concurrently 
with antibiotics, (as a prophylactic measure), and probiotic formularies that contained 
Lactobacillus or were multi-strained with Lactobacillus. Primary focus was placed on 
finding studies that reported the effects of utilizing probiotics on rates of CDI and 
evaluated the safety of probiotics. Secondary focus was placed on studies that evaluated 
cost-effectiveness of implementing probiotics in the in-patient hospital setting.  
 Nineteen articles were reviewed. The SALSA framework, (Search, Appraisal, 
Synthesis, and Analysis), was the structural base and process used to guide this scholarly 
inquiry project (Grant & Booth, 2009). Critical appraisal of each individual study was 
performed utilizing appraisal guidelines described in Gray, Grove and Sutherland, (2007) 
text.  Articles were scored for their level of evidence guided by: Ackley, Swan, Ladwig, 
and Tucker (2008). Hierarchy of evidence description can be viewed in Table B1. Level 
of Evidence.   By utilizing “SALSA” framework and the critiquing guidelines presented 
by Gray et al. (2009), and Ackley et al. (2008), Nineteen studies were noted to be most 
useful for the purpose of this review and are included in Tables C1- C19., Literature 
Review.  For each article critiqued; objectives, evaluation of the sample population, 
methods of study design, variables, and measurement tools were noted. Implications and 







Due to the controversial nature surrounding the topic of probiotic therapy, the 
efficacy of probiotics for prevention of CDI has been moderately studied (Vanden-
Nieuwboer, & Claassen, 2019). As a result, nine of the nineteen articles examined were 
systematic reviews and meta-analyses. Of the remaining articles, one was a qualitative 
review, and nine were individual studies ranging from cohort studies to multi-center 
randomized control trials. 
Several themes emerged following the review of literature. These themes 
included: variation in study sampling methods/flaws, variation in interventions, and study 
findings. To help guide the reader; a theme matrix may be found in Table D1. Theme 
Matrix. This theme matrix was constructed to delineate each individual study with the 
matching themes. Each theme was subsequently described in detail in the literature 
review section.  
Theme One: Study Methods 
 Study methods concerning sampling flaws, bias, and exclusion of high-risk 
patients poses a problem for prescribing providers as confidence in study findings may be 
lowered due to these factors. Sampling flaws, selection bias, and presence of 
heterogeneity lower the strength of the research findings. The issue of excluding high risk 
patients may decrease transferability of study findings into practice. Variability of what is 




Study heterogeneity and selection bias. Multiple authors of the systematic 
reviews, such as Lau and Chamberlain (2016), noted the complexity of ensuring 
heterogeneity while maintaining low risk of publication bias. This issue may leave 
providers unable to determine the interventions that are most effective in the reduction of 
CDI cases. Numerous variations in variables between each randomized control study 
poses a problem for systematic reviews and meta-analysis. This variability from study to 
study can result in a high level of heterogeneity. Due to the many differences between 
studies, the researcher is not able to verify the reliability of the study methods, due to the 
lack of replication in study designs.   
Three of the nine systematic reviews provided strong evidence to support low 
study heterogeneity, low risk of publication, and low selection bias. Johnston et al. 
(2012), Lau and Chamberlain (2016), and Shen et al. (2017), do not show any apparent 
risk of selection bias and reported statistics of low heterogeneity. This gave these studies 
good strength and credibility. These findings suggest that the studies being combined 
were alike and the data from the meta-analysis was credible. Low selection bias in these 
three studies suggested there was no researcher bias in the selection of the studies that 
were included in the analysis.  
A meta-analysis performed by the Cochrane group, authored by Goldenberg et al 
(2018), reported low risk of publication bias and no significant heterogeneity when 
analyzing studies that focused on CDI reduction. However, publication bias was present 
when the study focus was switched to adverse events instead of CDI reduction, resulting 




reported adverse events. Therefore, selection bias was eminent and resulted in a 
downgrade of certainty of evidence to low (Goldenberg et al., 2017, p. 24).  
The remaining five systematic reviews/meta-analysis poorly reported processes of 
controlling and analyzing for publication bias and ensuring heterogeneity (Hassan, 
Rompola, Glaser, Kinsey, & Philips, 2018;  Leal, Heitman, Conly, Henderson, & Manns, 
2016; Li et al., 2018; Pattani, Palda, Hwang, & Shah, 2013; Redman, Philips, & Ward, 
2014). Both Leal et al. (2016) and Li et al. (2018) did not report any statistics regarding 
heterogeneity, nor mention a process to determine publication bias. Hassan et al. (2018), 
Pattani et al. (2013), and Redman et al. (2014), vaguely reported presence of moderate 
publication bias. Yet, no further statistical values were given to determine the extent of 
bias present. Although these studies seem to provide valuable information and statistical 
analysis, complete confidence in their value cannot be determined due to these two 
factors. This is the biggest flaw of these studies. Through analysis of each individual 
study, the complexity of finding a group of individual studies that have similar variables 
is apparent. Little to no study replication was found in this review of literature.  
Poor sampling methods/study design. When the individual studies were 
analyzed, (disregarding  systematic review and meta-analysis), all ten of the individual 
studies had flaws in sampling methods and study designs. Despite the flaws, each study is 
believed to contribute value that can be used for further research.  
Seven of the studies were retrospective design studies (Box, Ortwine, & 
Goicoechea, 2018; Carvour et al., 2019; Dudzicz, Kujawa-Szewieczek, Kwiecien, 
Wiecke, & Adamczak, 2018; Kujawa-Szewieczek et al., 2015; Lewis et al., 2017; 




Bednarski, 2019). Retrospective designed studies pose the problem of a lack of 
randomization. This study method lacks control, as a result, risk factors or extraneous 
variables that may contribute to CDI reduction or proliferation may not be measured 
(Gray et al., 2017 p. 241). Due to high rates of internal and external threats to validity in 
retrospective designed studies, determining cause and effect relationships may be 
confounded (Tofthagen, 2012, p. 181). However, there is value to retrospective studies. 
These factors include financial feasibility, (compared to large randomized control 
studies), and design success and/or failures that can be used for design of further studies 
(Tofthagen, 2012, p. 181). 
All seven retrospective designed studies were single center cohort studies. 
Therefore, external validity, (extent to which research results can be generalized to other 
populations), cannot be fully determined. Another downfall of single center studies is 
insight to other unmeasured study variables or phenomena, such as differences in 
standards of care, cannot be determined unless specifically stated (Gray et al., 2017, p. 
199). However, these studies still provide insight that can be useful for further research. 
The last two studies by Selinger et al. (2013) and Guillemin et al. (2014), had 
sampling flaws. The Selinger et al. (2013) study, despite being a strong randomized 
control trial with good rigor, had a low power analysis. The power required for adequate 
sample size was calculated to be greater than 382 participants; the final number of 
participants was 122 (Selinger et al., 2013, p.161). Selinger et al. (2013) initially did have 
a higher total population sample (initial enrollment was 231). The study had a poor 
attrition rate resulting in a final study sample of 122 patients. This was lower than the 




Lastly, Guillemin et al. (2014) performed a qualitative study on the mental, 
physical, and emotional impact associated with the diagnosis of CDI. In this study, 
sampling methods initially were purposive. However, a portion of the sample population 
ended up being recruited under convenience sampling. The initial study was designed to 
control for selection bias by having a third-party agency enroll patients. Yet, a clinician 
who was involved directly with this patient population, helped to recruit patients 
(Guillemin et al., 2014, p. 99).  
These examples convey the need for further randomized control trials that are 
large enough to meet a power analysis of five percent level of significance, have rigor in 
sample selection methods, and have strong control on variables. Once high-quality 
individual studies are performed and further replicated, systematic reviews and meta-
analysis will then have less significant levels of heterogeneity between each individual 
study analyzed. In turn, the lower level of heterogeneity may provide researchers higher 
confidence in the meta-analysis findings.  
Exclusion of high-risk patients. Many of the studies analyzed excluded “high 
risk” patients due to concerns for risk of adverse events. For each of these studies the 
definition of high risk varied. Variability of “high risk” poses a problem for providers 
when analyzing these studies. Exclusion of high-risk patients may also decrease a 
provider’s ability to apply the concepts of the research into clinical practice. Determining 
the risk versus benefit ratio of probiotics for high-risk patient groups is difficult, due to 
lack of studies that include high risk patients. Probiotics may be safe and hold benefit for 




review did include a high-risk population sample, such as the article by Dudzcicz et al. 
(2018). 
Several studies report exclusion of high-risk patients (Lau and Chamberlain, 
2016; Lewis et al., 2017; Pattani et al., 2013; Selinger et al., 2013; Shen et al., 2017). 
Each study’s definition of high risk is defined differently. For example, Shen et al. (2017) 
defined “high risk” as: pregnancy, human immunodeficiency virus, previous organ 
transplant, undergoing chemo-therapy and/or radiation, prosthetic heart valves, admitted 
to an intensive care unit for any reason, and pre-existing gastrointestinal disorders of any 
type (Shen et al., 2017, p. 1891). Lewis et al. (2017) reported an exclusion of high-risk 
patients similar to Shen’s except the addition of the presence of a central venous catheter 
and unable to take medications orally (Lewis et al., 2017, p. 849). Both exclusion criteria 
are similar, yet different, leaving the high-risk exclusion criteria unclear. Of these five 
studies that do not include high risk patients, all have findings which supported the use of 
probiotics, but state that further research is needed due to study limitations.   
Several studies in this review did contain high-risk patient populations (Dudzicz 
et al., 2018; Hassan et al., 2018; Kujawa-Szewieczek et al., 2015; Maziade et al., 2013; 
Redman et al., 2014). These studies focused on high-risk patient population groups or 
included high risk patients. All five of the studies were based outside of the United 
States, however, were still in well-developed countries. For example, the study by 
Maziade et al. (2013), was performed in Quebec, Canada and included patients that have 
been excluded from prior Canadian randomized control trials for the following: recent 
chemotherapy use, presence of cardiac valves, patients within the intensive care units, 




by Dudzicz et al. (2018) is based in a nephrology and post transplantation ward. In the 
Dudzicz et al. (2018) study, all the post-transplant patients were receiving 
immunosuppressive medications, resulting in an immunocompromised state.  No 
significant adverse side effects, bacteremia or fungemia related sepsis, linked to probiotic 
administration were found in these studies.  
The culture of not prescribing probiotics to “high-risk” patient populations comes 
from multiple individual case studies citing the link of probiotics to sepsis. However, a 
recent systematic review by Costa et al. (2018) noted a lack of significant evidence to 
support this practice. Costa et al. (2018) performed a systematic review and meta-analysis 
of individual clinical reports and case studies related to serious effects related to 
Lactobacillus probiotic usage. The author found that there have been a total of 93 cases of  
septicemia and/or fungaemia related to all probiotic species types since 1976-2018 and of 
those 93 cases 26 were related to Lactobacillus probiotics since (Costa et al., 2018, p. 4). 
Studies analyzed within this review of literature, (19 articles, of which nine are 
systematic reviews), did not note any patients who experienced major adverse health 
events related to Lactobacillus administration. This leaves the provider questioning if 
such stringent inclusion criteria are necessary or if adequate research has yet to be 
performed.  
Theme Two: Intervention Methodologies  
High variability in intervention practices was an emerging theme in this review. 
Every study had differences in species, concentration/dosage, timing of initiation, and 
duration of the probiotics administered. This impedes providers from utilizing the highest 




administration was most beneficial for reducing CDI outcomes was unclear, due to lack 
of rigor within studies and lack of replication of studies.  
Probiotic species and dosage. Based on recommendations by the Cochrane 
group, the aim of the article review was to use studies that focused on probiotics that 
contained Lactobacillus (Goldenberg et al., 2017, p. 23). This was a difficult goal as 
many of the systematic reviews included different types of probiotic strains such as 
Bifidobacterium, and Saccharomyces boulardii. Even with studies that only focused on 
Lactobacillus probiotics, high variability across all the studies in concentration/colony 
forming units per dosage, and dosing frequency, were found. Once again, this factor was 
a major contributor to the high heterogenicity seen within all the systematic reviews.  
Many of the systematic reviews did not control specifically for the species type 
and dosage of the probiotics. For example, the systematic review by Hassan et al. (2018), 
performed statistical analysis of pooled data from 25 studies, in which the main 
population studied was cancer patients. Eighteen of the 25 studies reviewed contained a 
Lactobacillus probiotic. The results of the study appeared promising in the efficacy of 
probiotics. Yet, the authors disclosed that no conclusion of probiotic safety and efficacy 
could be determined due to the vast interventional heterogeneity present in the studies 
(Hassan et al., 2018, p. 2509). This was a common phrase and theme found in many of 
the systematic reviews.  Goldenberg et al. (2018), Hassan et al. (2018), Johnston et al. 
(2012), Lau and Chamberlain (2016), Leal et al. (2016), Li et al. (2018), Pattani et al. 
(2013), Redman et al. (2013), and Shen et al. (2017), all lacked rigor in their intervention 
design in regards to probiotic species and dosing frequency, and do not exclusively use 




researched multiple probiotic species but only the probiotics which contained a 
Lactobacillus species showed significant reduction in CDI (relative risk of 0.33, risk 
difference -.010, CI [-.5-.05] I² = 0.) (Pattani et al., 2013, p. e64). 
Box et al.’s (2018) retrospective cohort study attempted to control variability by 
only analyzing patients who received a probiotic formulation (which contained 
Lactobacillus), called “Bio-K”. Yet, because probiotic prescribing was left to the 
digression of the primary provider, high variability in dosage amount and frequency of 
dosing was found. As a result, high degree of prescribing bias was present (Box et al., 
2018, p. 2). There was a chance that only patients who providers believed were high risk 
for CDI were prescribed the probiotic. Due to the lack of a control group, confidence in 
the study findings are low. 
 Seven of the articles reviewed controlled the intervention by using a specific type 
of probiotic, all which contained Lactobacillus, these articles also specified the dosing 
amount and frequency (Dudzcicz et al., 2018; Kamdeu et al., 2012; Kujawa-Szewieczek 
et al., 2015; Lewis et al., 2017; Maziade et al., 2013; Sadanand et al., 2019; Selinger et 
al., 2013). For example, Dudzcicz et al. (2018), had a strong designed study with high 
rigor. This study analyzed CDI outcomes for patients in a nephrology and transplantation 
unit by administering a Lactobacillus containing probiotic called “LP299v”. The 
probiotic was administered orally, once daily, at the start of antibiotic administration, and 
continued for the duration of the antibiotic treatment. Due to the high quality of the study, 
Dudzicz et al. (2017) may be a landmark study to guide further research.  
Timing of probiotic administration. Timing of the administration of probiotics 




Within this review, there was high variability between studies on when interventional 
probiotics were administered. From analysis of the articles research it appeared the closer 
probiotics were started to the time of the initial antibiotic administration, the better the 
outcome in reference to CDI reduction (Shen et al.,2017).  
The effects of timing on probiotic administration and duration of treatment for 
CDI rates were analyzed by Shen et al. (2017). They reported statistically significant 
reduction in CDI rates in patients who received probiotics within one to two days of 
antibiotic administration, (relative risk 0.32, 95% CI .22-.48), compared to patients who 
received probiotics within three to seven days, (relative risk .70, 95% CI .40-1.23). This 
resulted in a significant difference in infection rates (p = .02), (Shen et al., 2017, p. 1896). 
Understanding of how probiotics work, and how antibiotics disrupt the micro bacterial 
state of the gastro-intestinal tract, this concept of starting a probiotic near the start of an 
antibiotics seems reasonable (Pattani et al., 2013, p. e65). Seven studies were clear on 
their probiotic initiation and administration time frame: Dudzicz et al. (2018), Kamdeu-
Fansi et al. (2012), Kujawa-Szewieczek et al. (2015), Lewis et al. (2017), Maziade et al. 
(2013), Selinger et al. (2013) and Shen et al. (2013), all initiated probiotics either at the 
time of antibiotic administration or within three days of antibiotic start.  
One large well-designed randomized control trial called the PLACIDE study by 
Allen et al. (2013), failed to initiate a probiotic intervention in a timely manner. This 
study found lowered but not significant findings on probiotic efficacy in reducing CDI 
rates. However, in the study’s intervention process probiotics were initiated up to seven 




this study, the timing variable alone could be one of the factors as to why probiotics did 
not significantly reduce CDI rates within this study.  
Information on timing/ initiation of probiotics was not always included in the 
studies. This is problematic as this variable appeared to be an important factor on the 
efficacy of probiotics. More research is needed to determine when the administration of 
probiotics results in the highest benefit. In this review, probiotics started at the time of 
first antibiotic administration and up to two days after seemed to hold the most benefit in 
significant reduction of CDI (Dudzicz et al., 2018; Kamdeu-Fansi et al., 2012; Kujawa-
Szewieczek et al., 2015; Lewis et al., 2017; Maziade et al., 2013; Selinger et al., 2013; 
Shen et al., 2013). 
Theme Three: Findings  
Returning to the main purpose of the review; the efficacy of probiotics on 
reducing the rates of CDI in hospitalized patients undergoing  antibiotic therapy, 
determining if they are  cost effective, and  safe. As noted with the previous themes 
discussed, there are many hinderances in both the background methods and interventional 
methods that make a final conclusion on the efficacy and safety of probiotics difficult. 
However, in this literature review, Lactobacillus probiotics appeared to have a positive 
effect on reducing CDI rates, appeared to be cost-effective, and do not seem to have more 
adverse events/side effects than a control or placebo intervention.  
Decreased Clostridium difficile infection rates. Twelve out of the 16 studies that 
had an outcome measure analyzing the effect of probiotics on CDI rates, provided 
evidence to support the use of probiotics as a means of CDI prevention. However, due to 




future studies are needed to fully support the use of probiotics with high confidence. The 
lack of rigor and poor study designs leave the validity of the research findings unclear.  
Goldenberg et al. (2018), which is considered a landmark study on the subject of 
probiotic efficacy, found prophylactic probiotics are effective but most useful in hospitals 
in which preintervention rates of CDI is greater than five percent. In environments with 
baseline CDI rates greater than five percent, the implementation of probiotics may result 
in a 70% risk reduction (Goldenberg, et al., 2018, p. 19). Among the other studies that 
were of moderate quality, the average risk reduction of CDI ranged from 33-40% with an 
average of 35.6% reduced risk of CDI (Johnston et al., 2012; Leal et al., 2018; Pattani et 
al., 2013; Shen et al., 2017).  
Although the article by Dudzicz et al. (2018) was a retrospective single center 
study, their design had high rigor, (in terms of dosing, timing of administration and 
duration of probiotic treatment). Their inclusion of high-risk patient population and rigor 
within the study design, may make this study a future landmark study. Their findings 
showed a significant decrease in rate of CDI during the implementation period of a 
Lactobacillus containing probiotic called “LP299v” administered once per day with the 
start of any antibiotic. The incidence rate of CDI declined from 10.3 cases per 1,000 
patients, down to 1.1 cases per 1000 patients, (p = 0.0003). This was a significant finding. 
When researchers discontinued probiotics in phase three of their study, CDI rates again 
increased and matched preintervention rates (Dudzicz et al., 2018, pp. 5-7). Despite study 
flaws and poor designs seen within many of the studies, probiotics consistently seem to 
be effective as a prophylactic measure for CDI reduction (Butler et al., 2016, p. 21).  The 




reason for why they termed evidence of probiotic efficacy as moderate quality 
(Goldenberg et al., 2017, p.5). 
 The studies that do not support probiotics as a CDI reduction method also have 
many flaws. For example, high prescriber bias, was seen in the study by Box et al. 
(2018), where probiotic prescribing was left solely to the digression of the prescribing 
provider. This further supported that probiotics may be efficacious when noting the 
quality of the studies that did not support probiotics had lower appraised quality than 
their counter part. However, the lack of overall quality, rigor, and heterogeneity between 
studies leaves the researcher unable to state with high level of certainty that probiotics are 
effective. Due the study design flaws, this research review finds that probiotics are likely 
effective for reducing CDI rates, but only can be concluded with a low to moderate level 
of certainty due to poor study design. 
Cost effectiveness. Cost effectiveness was an important finding to analyze. Cost 
effective analysis is often needed  to gain support from stakeholders in a hospital setting 
(Melnyk & Fineout-Overholt, 2015, p.474). Six studies discussed the cost related savings 
and benefits of using probiotics. Dudzicz et al. (2018), Kamdeu et al. (2012) and Li et al. 
(2018), provided the most evidence of cost savings in this literature review. 
Dudzicz et al. (2018) performed a study in which patients in a nephrology and 
transplantation ward received a probiotic called “LP299v” orally, once per day. The 
result was a decrease in CDI rates from 10.3 per 1,000 patients to 1.1 cases per 1,000 
patients, (p = 0.0003) (Dudzicz et al., 2018, p.5). Cost to implement a probiotic as a 
prophylactic measure, for an average of 14 days was about four dollars and fifty cents. 




was about 68.9 dollars. This is a significant finding, as one case of CDI can cost an 
average of 8,000 dollars to treat (Dudzicz et al., 2018, p. 9).  
Kamdeu-Fansi et al. (2012) performed a formal cost benefit analysis on a study 
that was previously performed by Gao et al. (2010). Despite the study being originally 
performed in China, Kamdeu-Fansi et al. (2012) performed adjustments for the 
differences in currency value to match costs of American pharmaceuticals and hospital 
products. They performed this by utilizing the American Consumer Price Index to 
determine the cost adjustments. In the study there were three cohorts; one placebo group, 
one group who received one “Bio-K+” probiotic daily, and one group that received two 
capsules of the “Bio-K+” probiotic, once per day. The authors made five major 
assumptions based on typical care practices. They assumed CDI testing would be 
performed by a microbiological screening test.  They assumed, after CDI diagnosis, 58% 
of patients would be treated with Metronidazole and 42% would receive Vancomycin. 
They assumed Metronidazole would fail in 26% of the cases (based off current literature 
findings). They also assumed that patients with CDI would have a prolonged length of 
hospital stay (Kamdeu-Fansi et al., 2012, pp. 56-57). For cohort one (placebo), they 
found an average additional length of hospital stay was six toseven days. Cohort two 
average hospital length of stay was four days, and cohort three average length of hospital 
stay was two to three days. For those who were diagnosed with CDI, the additional 
hospitalization costs were about 1,424.16 dollars per day (Kamdeu Fansi et al., 2012, 
p.56). Therefore, utilizing these assumptions and study findings, if all patients who are at 
risk of CDI are given one probiotic once per day, due to the subsequent decrease in total 




probiotic. In the scenario for those who received two capsules of the Bio- K+ probiotic, 
the cost savings were closer to 2,661 dollars, per patient treated with the probiotic 
(Kamdeu-Fansi et al., 2012, p. 56). Utilizing the average CDI rate per 1,000 patients in 
American hospitals, prophylactically treating 1,000 patients with two capsules of 
probiotics, once per day, during their antibiotic course, could result in a cost savings of 
1,680,000 dollars annually (Kamdeu-Fansi et al. (2012, p.59). This study was based 
solely on hospital costs and did not take into account quality of life cost adjustments.   
Li et al. (2018) also analyzed in-hospital costs but adjusted the analysis to include 
burden on quality of life indicators. Li et al. (2018) suggest cost savings to an institution 
was higher when taking into consideration the quality of life effects. They reported 
savings were closer to 3,686 dollars per patient treated with probiotics due to the 
decreased overall rates of CDI and decreased quality of life burden (Li et al., 2018, p. 
473). 
These findings are highly significant when discussing cost savings to an 
institution. Each case of CDI was associated with increased length of hospital stay, 
increased need in medical cares, and increased mortality rates. Quality of life adjustments 
with this infection are equally important to consider. In a qualitative study by Guillemin 
et al. (2014), authors explored the perceived burden associated with CDI from the 
patient’s lived experience. They highlight that the diagnosis and symptoms associated 
with CDI were highly burdensome and found data saturation on the negative effects the 
infection had on psychological and emotional health of patients. They find increased 
negative effects on an individual’s professional life and an increased financial burden 




increased required payment for hospital services and additional time off work that was 
required post hospital discharge (Guillemin et al., 2014, p. 100). The article was an 
excellent example of how healthcare associated costs to a facility are not the only aspects 
to consider when a cost-benefit analysis is performed. Quality of life measurement 
continues to be an important aspect to consider in an analysis of cost versus benefit (Li et 
al., 2018). As shown in the Guillemin et al., (2016) study, CDI affected patients’ lives 
due to the increased length of hospital stay, increased embarrassment felt by the patient, 
and financial implications due to lost time at work (Guillemin et al., 2016). 
Adverse side effects. The last finding analyzed was to determine if there were 
significant differences in adverse side effects with the use of an interventional 
Lactobacillus probiotic group compared to a placebo group. This was a very important 
variable to determine for future studies as implementation of an intervention that is 
known to be harmful to a patient would be unethical. As noted in the exclusion of high-
risk patient section, there is hesitancy to use probiotics on patients due to a concern for 
increased chance of blood stream infections related to probiotic use. This practice was 
based off individual clinical reports and case studies. Again, according to Costa et al. 
(2018) there was significant lack of evidence to support this practice. Six studies were 
included in this review based on their inclusion of “high-risk” patients. All six of the 
studies found no significant difference in adverse effects related to a probiotic group 
versus a placebo group.  
Hassan et al. (2018) focused on a sample population group with cancer. They 
found that adverse events in the intervention group (n = 237) were lower than that in the 




provide a statistical analysis to determine if this finding was significant. However, their 
inclusion of the high-risk patient population is important to note. Sadanand et al. (2019) 
performed a single -center retrospective study on pediatric hemopoietic stem cell 
transplant patients. These patients received a Lactobacillus containing probiotic as a 
treatment method for graft versus host disease. No cases of blood stream infections while 
patients were on probiotics were found. (Sadanand et al., 2019, p. 304). Although this 
study did not exclusively look at CDI infection, the study is included as an important 
supporting factor for the safety of probiotics. These post transplantation pediatric patients 
were receiving immunosuppressive medication. Yet, there were no severe adverse events, 
such as probiotic related septicemia, seen in this study related to probiotic usage 
(Sadanand et al., 2019, p. 305).  
Goldenberg et al. (2018), Johnston et al. (2012), and Shen et al (2017) all 
performed analysis on adverse event variables and provided statistical data to support 
their findings. Goldenberg et al. (2018) found statistically significant data which 
supported less adverse side effects in the probiotic group over placebo. However, due to 
the high publication bias present within the systematic review and meta-analysis, this 
study’s findings were inconclusive (Goldenberg et al., 2018). Johnston et al. (2012), 
found when comparing the adverse events in a placebo group versus a probiotic treatment 
group, there was a relative risk reduction of 0.82, with a 95% confidence interval of 0.65-
1.05. Thus, the authors supported the safety of the probiotic intervention. The authors 
noted the evidence classified as moderate quality evidence (Johnston et al., 2012, p. 884). 




placebo group to intervention group (p = 0.35), in their study (Shen et al., 2017, pp. 
1894-1895). 
Literature Review Summary 
 The efficacy of probiotics  remains unclear. There likely is benefit to the use of 
probiotics as a prophylactic measure to reduce CDI occurrence within the hospital 
setting. The main hinderance to this subject’s clarity is the lack of strong study methods 
and backgrounds and high heterogeneity between many of the studies analyzed within the 
systematic reviews analyzed. Individual studies lacked rigor and randomization. This 
conclusion was consistent with findings and recommendations posted by the Agency for 
Healthcare Research and Quality (AHRQ), Comparative Effectiveness Review. They 
listed probiotics as a treatment option with low quality of evidence but consistent 
findings of efficacy (Butler et al., 2016, p.21). They also found the prevention methods: 
antibiotic stewardship and handwashing, to also have low quality of evidence. Other 
measures such as chlorhexidine bathing, ultraviolet room cleaning, and hydrogen 
peroxide cleaners, do not have sufficient evidence to support these practices as evidence-
based methods (Butler et al., 2016, p. 15). Therefore, Butler et al. (2016) argued that the 
low quality of evidence should not rule out usage of probiotics as antibiotic stewardship 
and handwashing continues to be a widely accepted hospital practice.  
 A theme noted in many of the studies was exclusion of the high-risk patient 
population. This concept stemmed from a few case studies where blood stream infections 
were believed to be from the use of a probiotic. A compelling article by Costa et al. 
(2018) found this concept to be rare and not a reliable reason to exclude high risk 




high-risk population group- such as stem cell transplantation patients and cancer patients. 
No adverse events were found in any of the studies contained within this review of 
literature. Therefore, in order to strengthen support for the use of probiotics more high-
quality randomized controls studies that have rigor and high control need to be performed 
and less stringent exclusion criteria may need to be considered.  
   Within this review, a few intervention methodologies were sought including a 
probiotic intervention that contained Lactobacillus, and studies that analyzed the effect of 
the timing of initiation of a probiotic. The concept of focusing on studies that contain a 
Lactobacillus component was guided by current recommendations from the Cochrane 
group (Goldenberg et al., 2017). Studies that analyzed the effect on the timing of 
probiotic administration noted higher success with CDI reduction when a probiotic 
intervention was initiated within three days of antibiotic administration (Dudzicz et al., 
2018; Kamdeu-Fansi et al., 2012; Kujawa-Szewieczek et al., 2015; Lewis et al., 2017; 
Maziade et al., 2013; Selinger et al., 2013; and Shen et al., 2013). 
 Overall findings for the initial PICOT question are difficult to answer due to the 
study flaws previously mentioned. Therefore, overall support for the use of probiotics is 
supported within this review with only low to moderate confidence. This matches the 
current Cochrane handbook’s consensus of their review of the literature (Goldenberg et 
al., 2017). They too noted the quality of evidence to support the use of probiotics as a 
preventative measure for CDI as “moderate”. The AHRQ noted the evidence for use of 
probiotics as low but was consistently effective for reduction of CDI rates. The low rating 
was due to high heterogeneity between studies analyzed (Butler et al., 2016, p.121). 




probiotic treatment was implemented. Of the remaining four articles, two did not support 
the use of probiotics (Box et al.,2018; Carvour et al., 2019). These two studies had 
severely flawed study methods which rendered the quality of the studies as low. The 
remaining two articles suggested reduction in cases of CDI; however, findings were not 
statistically significant (Johnston et al., 2012; Li et al., 2018).  
 Cost effectiveness of probiotics is supported by this review of the literature. Cost 
savings could be as high a 2,661 dollars per patient treated with a probiotic as a 
prophylactic measure (Kamdeu-Fansi et al., 2012, p. 56). This finding was due to the 
resultant overall decrease in hospital acquired cases of CDI (Kamdeu-Fansi et al., 2012, 
p. 56). Utilizing the average CDI rate per 1,000 patients in American hospitals, the 
implementation of treating 1,000 patients with two capsules of probiotics once per day, 
during their antibiotic course, may result in a cost savings of 1,680,000 dollars (Kamdeu-
Fansi et al., 2012, p. 56). 
 No significant difference in adverse effects experienced by a probiotic 
intervention group over a control group was found in this literature review. Inclusion of 
studies with high risk patients was performed to aid in analyzing the safety of probiotics 
(Dudzuczet al., 2018; Hassan et al., 2018, Kujawa-Szewieczek et al., 2015; Mazaide et 
al., 2013; Reman et al., 2014; Sadanand et al., 2019). No major adverse events were 
found in the high-risk population groups that were exposed to probiotic treatment. These 
compounded findings support the safety of the use of probiotics.  
 Overall, the literature contained within this review supports the use of a 
Lactobacillus containing probiotic when initiated within three days of antibiotic start, as a 




review supports probiotics as a safe and cost-effective measure to reduce Clostridium 
difficile incidence within the hospital setting. Due to the flaws within each study 
confidence in these findings can only be rated as low to moderate. However, as stated by 
Goldenberg et al, (2018) probiotics have the highest quality evidence among cited 
prophylactic therapies including handwashing, daily room cleaning, contact isolation, and 
antibiotic stewardship, yet are not included in prophylactic clinical practice guidelines 
(Goldenberg, et al., 2018, p. 21) Yet to move forward, support for further high-quality, 
large, randomized control trial research is needed before institutional prescribing 







 A conceptual framework was constructed to aid readers to better understand the 
phenomenon of interest- Lactobacillus probiotics. As can be viewed in Table E1. 
Conceptual Analysis Components, the concept of interest was identified, antecedents and 
consequences are explained, and the level of evidence, (which was used to support this 
framework), was provided. The purpose of the pictorial framework provided in Figure 1., 
was to provide visual explanation of how each of the variables related to one another and 
show the consequential relationship or outcome of the concept. 
Relationships Identified 
As can be viewed in Figure 1., a negative relationship was seen for the variables 
of Clostridium difficile infection rates. This indicates that as the concept of interest is 
implemented (a Lactobacillus containing probiotic), rates of CDI are decreased, (Dudzicz 
et al., 2018; Goldenberg et al., 2018; Johnston et al., 2012; Kamdeu Fansi et al., 2012; 
Kujawa-Szewieczek et al., 2015; Lau & Chamberlain, 2016; Leal et al., 2016; Lewis et 
al., 2017;  Li et al., 2018; Mazaide et al., 2013; Pattani et al., 2013; and Shen et al., 2017).  
When probiotics were administered there was neither a positive or a negative 
relationship seen in terms of adverse events. There was no significant difference seen 




Johnston et al., 2012; Kujawa-Szewieczek et al., 2015; Lau & Chamberlain, 2016; 
Mazaide et al., 2016; Redman et al., 2014; and Sadanand et al., 2019).  
The final consequence examined was cost versus benefit. As the concept of a 
Lactobacillus probiotic was implemented, there was a positive relationship on 
institutional cost savings (Dudzicz et al., 2018; Hassan et al., 2018; Kamdeu-Fansi et al., 





Conclusions/Recommendations, and Implications 
Introduction 
Heath care acquired CDI is a highly virulent bacterial infection associated with 
increased patient mortality rates, increased costs to hospitals, and an increased burden on 
a patient’s overall quality of life (Center for Disease Control, 2017; Guillemin et al., 
2014).  Strategies that are known to decrease the incidence of CDI should be examined. 
Probiotics utilized for the prevention of CDI has been highly speculated and remains a 
controversial topic in healthcare (Vanden-Nieuwboer & Claassen, 2019). This literature 
review, aimed to investigate the effects probiotics have on reducing incidence of CDI in 
patients who were hospitalized and on antibiotics, whether the probiotic intervention was 
safe, and if a probiotic intervention was cost effective. Nineteen total studies were 
examined and critiqued for their credibility and quality. Several concepts emerged within 
the literature review including flaws in study design, high heterogeneity, presence of 
selection bias, and significant variability in intervention methodologies (concerning 
species, dosage, duration, and initiation of probiotic). Analysis of study findings suggest 
there is a low to moderate effect of a probiotic on CDI reduction, no evidence of adverse 
effects related to probiotic usage compared to placebo or no intervention, and data 
supporting institutional cost savings related to probiotic implementation. However, due to 
the lack of replicated studies and lack of data to support specific prescribing practices, 
more research is warranted. Until then prescribing practices should be left to the 
discretion of the prescribing provider, who should consider patient preference, and weigh 





Overall, the literature contained within this review supported the use of a 
Lactobacillus containing probiotic when initiated within three days of antibiotic start, as a 
measure to reduce CDI incidence within a hospital setting. This can only be stated with 
low to moderate certainty due to the high heterogeneity seen within most of the 
systematic reviews and poor methodology and study design seen within individual 
studies. 
The evidence supported probiotics as an effective measure to reduce Clostridium 
difficile incidence within the hospital setting. Despite many studies excluding high-risk 
patients, the articles which did include high risk patients did not find any significant 
evidence of an increased risk for adverse events. The concept of excluding high risk 
patients may be an outdated theory based on a small volume of case studies suggesting 
septicemia related to probiotic usage. This topic should be further addressed with more 
research.  
The cost-benefit analysis of probiotics and the savings to an institution seemed 
promising. When adding in a patient’s quality of life measures, support for the use of 
probiotics was further increased. There is hope that the potential financial savings from 
this intervention will be appealing to many institutions. Ideally as a result, support for 
further research within the institutions should occur and be funded.  
During the literature review process and analysis of the current evidence, links to 
implications for nursing and advanced nursing practice were addressed, probiotics may 
be a safe and inexpensive way to further decrease incidence of CDI. As antibiotic 




aspects of care need to be considered. Further research is needed on dosage, length of 
treatment. And the use of probiotics in high risk patient populations. The practice of 
including high risk patients in current studies is relatively new and studies that have been 
performed lack a strong design and quality.  
Implications and Recommendations 
 Studies focused on probiotics will continue to emerge with new evidence in the 
coming years. As advance healthcare providers, keeping up to date on the emerging 
evidence will be important. As bacteria and viruses continue to evolve and become more 
resistant, the increased risk of hospital acquired CDI needs to be evaluated and measures 
to combat infection prevalence need to be taken.  
For now, a full institutional change to support routinely prescribing probiotics to 
patients on antibiotics is not supported. However, prescribing of a Lactobacillus probiotic 
to an average risk patient who is taking antibiotics would not be against the current 
evidence. Recommendations for the optimal probiotic prescription: the frequency, dosing, 
and duration of the prophylactic treatment is not clear in the evidence.  At this time, 
providers should practice their critical thinking skills as well as right to autonomy and 
prescribe probiotics on a case to case basis. Consideration of patient preference should be 
included. Patients that are offered a probiotic supplement should be educated on the risks 
of taking a probiotic and the risks associated with not taking a probiotic. Again, the risk 
versus benefits, would be based on each patient’s clinical presentation and state of health. 
Providers and all healthcare workers should continue to use accepted strategies to prevent 
CDI infection in the hospital setting including proper hand hygiene, antibiotic 




To advance the current evidence, advanced practice nurses and providers should 
provide the current research findings and flaws to hospital stakeholders with hopes that 
funding for more rigorous research will occur. Further research should be based off 
strengths of previous studies. Future studies should have a strong control on variables and 
detailed explanation of the research process. Ideally, a double-blind randomized control 
trial utilizing multiple hospital institutions should be performed. Within all of these 
institutions. the same brand, dosage, and frequency of administration, and initiation of the 
probiotic or placebo should be completed. Study expectations should be clear on 
prescribing goals and probiotics should be initiated within three days of antibiotic start. 
The method and practice for testing CDI should be uniform, and current institutional 
standard of practice for infection prevention, pre-intervention should be similar. A 
universal reporting protocol should be in place to report adverse events with the probiotic 
use.  
Once further research is completed, if the evidence supports the use of probiotics 
with high confidence, hospital stakeholders should be re-engaged to determine if an 
intuitional change will be supported. If change is supported guideline development and 
education to prescribing providers should be performed. Guideline development and 
clinical decision support tools which could flag a provider that a probiotic should be 
considered when high risk antibiotics are prescribed, would be helpful. Once again, these 
would only be indicated once more rigorous and precise research is performed and if the 
research obtained supports the use of probiotics. 
At this time, providers are recommended to remain current on emerging evidence 




weigh the benefits versus risk of using probiotics on case to case basis. As always, patient 
preference should be determined, and patients should be educated on the benefits versus 
risk of using a probiotic supplement. 
Summary 
Research contained within this review of literature supports the use of probiotics   
administered concurrently with antibiotics as a prophylactic measure to prevent CDI in 
the hospital setting with moderate certainty. Evidence supports that probiotics have low 
associated risk with usage for those who are not immunocompromised.  Cost savings is 
apparent within the studies analyzed.  However, due to high heterogeneity seen between 
each individual study and lack of study replication, confidence in these study findings is 
low to moderate.  
At this time providers should engage in reviewing emerging evidenced based 
research that emerges. Consideration for the use of a probiotic supplement should be 
gauged on a patient to patient basis and risk versus benefit of probiotic usage should be 
analyzed. As with any care provided, patient preference should be analyzed. Patients 
should be educated on the benefit and risks associated with the usage of a probiotic 
supplement, as well as, the risk associated with not utilizing the supplement.  
Advanced practice providers should continue to be at the forefront of pursuing 
research. Once further high-quality research with high rigor is performed, data found 
within those studies can be used to support or not support an institutional change. Until 
then, all healthcare providers should continue to practice universal infection control 




providers should use critical thinking and autonomy to determine the benefits versus risk 
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Clinical Definition and Recommended Treatment for Clostridium difficile Infection in Adults 
Clinical Definition Signs/Symptoms  Recommended Treatment Methods  
Initial Episode- Mild  Leukocytosis less than 15,000. Serum 
creatinine less than 1.5mg/dL 
First line treatment: Vancomycin 125mg every six hours for ten days.  
Or 
Fidaxomicin 200mg twice per day for ten days  
If neither Vancomycin or Fidaxomicin are available: Metronidazole 500mg three 
times per day for ten days.  
Initial Episode 
Moderate 
Leukocytosis greater than 15,000  
Creatinine greater than 1.5mg/dL  
First line treatment: Vancomycin 125mg every six hours for ten days.  
Or 
Fidaxomicin 200mg twice per day for ten days 
Initial Episode Severe  Leukocytosis greater than 15,000  
Creatinine greater than 1.5mg/dL 
Hypotension, shock, ileus, mega colon  
Vancomycin 500mg every six hours via mouth or nasogastric tube.  
If ileus is present add rectal instillation of Vancomycin 500mg every six hours 
AND  
Intravenous Metronidazole 500mg every eight hours  
First Recurrence   If Metronidazole was used for first episode: Vancomycin 125mg every six hours 
for ten days 
Or 
Prolonged taper of Vancomycin 125mg every six hours for 10-14 days then 
125mg twice per day for seven days, then once per day for seven days, Lastly 
once every three days for two to eight weeks  
Second Recurrence   Prolonged taper of Vancomycin (see above)  
Or  
Vancomycin 125mg every six hours for 10 days followed by Rifaximin 400mg 
three times daily for twenty days  
Or  
Fidaxomicin 200 mg twice per day for ten days  
Or  
Fecal microbiota transplantation  








Database Search  
Date of 
search 
Key Words Used  Database used  Listed Reviewed  Used  
1/29/19 Prophylactic Probiotic and 
Clostridium difficile and 
Antibiotics 
CINAHL  18 14 1 
2/6/19 Clostridium difficile, Probiotics, 
Hospital  
PubMed  44 15 2 
2/20/19 Patient Experience and 
Clostridium difficile  
CINAHL 36 3 1  
3/1/19 Probiotic, Clostridium difficile  Cochrane  23 1 1 
3/10/19 Probiotic OVID 2 2 0 
3/10/19  Economic Burden, Clostridium 
difficile 
PubMed 112 4 1 
3/12/19 Probiotics, Reduce, Clostridium 
difficile  
Google Scholar  1989 2 0 
3/15/19 Cost Analysis, Probiotics, Reduce 
Clostridium difficile  
Cochrane  2 1 1 
3/19/19 Cost, Probiotics, Clostridium 
difficile  
PubMed  14 3 1 
10/23/19 Probiotics and Clostridium 
difficile  
EBSCOhost  214 9 3 
11/1/19 Cost Effectiveness, Probiotics  PubMed  36 4 2 
11/15/19 Safety, Probiotic  CINAHL  194 20 3 








Table C1.  
Level of Evidence Key  
Level of evidence 
(LOE) Description 
Level I Evidence from a systematic review or meta-analysis of all relevant RCTs (randomized 
controlled trial) or evidence-based clinical practice guidelines based on systematic reviews of 
RCTs or three or more RCTs of good quality that have similar results. 
Level II Evidence obtained from at least one well-designed RCT (e.g. large multi-site RCT). 
Level III Evidence obtained from well-designed controlled trials without randomization (i.e. quasi-
experimental). 
Level IV Evidence from well-designed case-control or cohort studies. 
Level V Evidence from systematic reviews of descriptive and qualitative studies (meta-synthesis). 
Level VI Evidence from a single descriptive or qualitative study. 
Level VII Evidence from the opinion of authorities and/or reports of expert committees. 
 Note. The level of evidence scheme is based on a studies quality in design, validity, and applicability to care. The higher the 
level of the evidence, the greater the strength in the study. This level of evidence key is based on literature by: B. J., Swan, B. 
A., Ladwig, G., & Tucker, S. (2008). Evidence-based nursing care guidelines: Medical-surgical interventions. (p. 7). St. 








Table D1.  



















































n = 927.  
-Setting: 400 bed 
community 
hospital in La 
Jolla, CA.,   
March 29th 2016-
Sept 30th 2016.  
 -Inclusion: 
Patients >18 




had a hospital 
stay >3 days.   
-Exclusion: CDI 
diagnosis within 




study   
-Scripps Institutional 
review board 
approved   
 -Probiotic 
prescribing left to 
providers discretion.   
 -Not randomized: all 
patients on antibiotic 
included in study. 
Any patients who 
received probiotics 
were in the 
intervention group.  
-Demographic data 
analyzed: length of 
stay, number of 
antibiotics used, ICU, 
mortality rates, and 




2 tailed students T-
tests, and fishers 
exact tests. 
-Each cohort was 
not demographically 
similar (statistical 
difference in ICU 









CDI   
CDI difference- not 
statistically 
significant (p = 
0.16).   
 
Patients in the 
probiotic group 
had a longer 
length of stay, 
higher “Charlson 
co-morbidity 
index”, and higher 
amount of 
antibiotics given.  
Thus, results are 
likely skewed    




initiated from the 
start of 
antibiotics.   
  
Did not analyze 
type of antibiotic 
prescribed   
Authors do not recommend 
the use of probiotics due to 
insufficient evidence  
 Prescribing of probiotics was 
not a required practice, it was 
at the discretion of the 
provider. This may lead to 
skewed results as the 
physician may have 
prescribing bias- higher risk 
patients   
  
Flaw of study was they did 
not analyze the type of 
antibiotics prescribed with 
each group to assess for 
heterogeneity. Some 
antibiotics carry a higher risk 
in association to CDI rates.   
  
Authors note their methods 
of leaving prescribing 
practices to the physicians is 
more real-world applicable. 
However, this variable allows 
for high bias.   
IV 
Note.  LOE = level of evidence, N = total sample population, n = subset population, CDI = Clostridium difficile infection, ALESC = A Language and 
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Carvour et al. 
(2019) 
 








the goal of 
decreasing 
CDI rates.  



















may be present.  
-Poorly designed case 
control cohort study.  
-Retrospective chart 
analysis from 2011-2016 
used the clinical 
identifying factor of CDI 
assay test from data 
warehouse. 
-Those who were tested 
for CDI assay negative 
or positive were 





utilizing SAS version 
9.4.  
-Variables searched 
against: location of 
diagnosis or initial test, 
probiotic use, current 
steroid use, diabetes, 
current proton pump 
inhibitor medication use, 
and month of diagnosis   
Significant 
difference in age 
of diagnosis. 
Patients who are 
greater than 65 
years of age = 
higher risk (p = 
0.08). 
Diagnosis in ED 
more prevalent 
than any other 
patient care area 
(p = 0.0001). 




having CDI (p = 
.01). Probiotic 
usage in last 180 




chart analysis has 
many flaws.  
Analyzing previous 
probiotic usage prior 
to admission, these 
findings are highly 
biased as clients may 
have initiated 
probiotics due to 
symptoms associated 
with CDI such as 
diarrhea. 
 Due to the 
retrospective aspect 
of the study, this 
factor cannot be 
clarified therefore is 
not a clear link of a 
risk of probiotic use. 
   
Due to information 
regarding when probiotics 
were started and for what 
purpose, stating probiotics 
may be unsafe and may 
cause CDI cannot be fully 
inferred.  
Randomization was lacking 
as any patient suspected of 
CDI was included in study. 
-There was a high degree 
of selection bias. 
The study provides good 
insight of possible factors 
that may be related to CDI 
rates, however due to the 
design and quality of the 
study, no true inferences 
can be made.  
  
IV 








Literature Review  
Note: LOE = level of evidence, CDI = Clostridium difficile infection, LP299V = Lactobacillus plantarum 299v, N = total sample population, n = RR = 



















































ssion therapy  
-N = 5341 
-n = 24 (total 
patients on 
immunosuppressiv
e therapy and 
antibiotics over 3-
year period who 
developed CDI). 
-12-month pre -
intervention: n = 
10 
-12-month during 
intervention: n = 2 
-12-month post 
intervention: n =12 
-Sample: Patients 




e therapy and 
antibiotics (any), 
age greater than 18 






single-center study.  


















of no probiotic.  
 Data analyzed 
with STATISTICA 
12.0PL, Chi² tests, 
and an alpha 0.05 
After initiation of 
LP299v prophylaxis, 
incidence rate of CDI 
significantly declined- 
10.3 to 1.1 per 1000 
patients (RR 0.11; 95 
% CI [0.03–0.47], p = 
0.0003).  
-After cessation of 
probiotic, CDI 
significantly increased 
from 1.1 to 7.7 per 
1000 hospitalized 
patients (RR 6.93; 
95% CI [1.58–30.47], 
p = 0.0028 
-Average prophylaxis 
duration was 14 ± 7 
days. 
- The cost of CDI was 
17.5 PLN (4.1 €) per 
one patient (converted 
to USD = 4.5 dollars). 
cost of prevention for 
one case of CDI is 
262.5 PLN (61.5 €) 
(Converted to USD = 
68.9 USD) 

























n groups  
Interesting the study 
was done in Poland as 
this likely would not 
be approved by IRB 
board in United States 
as administration of 
probiotics to 
immunocompromised 
patients is theorized to 
be dangerous.  
-This study may in the 
future be considered a 
landmark study 
supporting use for 
patients who are 
immunocompromised 
-H2 blockers was 
noted to be used in 
82% of patients who 
were positive for CDI 
-Included cost savings 
and cost needed to 
benefit one patient. 
-Supports the use of 
probiotics and does not 
find any adverse 
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any route and 
received 
probiotics of 
any species or 
concentration
. 
- Setting: 13 
countries 







-Systematic review with 
meta- analysis 
-4 search engines utilized 
(PubMed, Embase, 
Central, and Cochrane).  
-Included studies from 
1966-2017 
-Two trained reviewers 
screened abstracts. 
-Selection bias controlled 
by use of Cochrane 
Handbook for Systematic 
Review of Interventions  
-Each study scored for 
quality by GRADE criteria 
-Statistical analysis by 
RevMann Software 
- Reported RR with 95% 
CI, and NNT 
-Analyzed heterogeneity 
with funnel plot for both 
CDI incidence and adverse 
events   
-Baseline risk percentages 
in relation to risk reduction 
rate 
-Heterogeneity analysis for CDI 
incidence = (p = 0.79) (low risk of bias 
- Heterogeneity analysis for adverse 
events (p = 0.05) (moderate risk of 
bias) 
- CDI incidence in intervention group 
versus control: intervention group = 
1.5% (70/4525), CDI incidence in 
control = 4% (164/4147), RR = .40, 
95% CI [0.30-0.52], NNT = 42, 95% 
CI [32-58] 60% risk reduction, 
GRADE score = moderate.  
-Adverse effects in intervention group 
versus control:  
-Intervention: 170/1000 = 1.7% versus 
control: 141/1000 = 1.4%,  
RR= .83, 95% CI [0.71-0.97]  
GRADE score = low 
-Baseline risk of 0-2% not significant 
reduction in CDI with probiotics (p = 
0.34) 
-Baseline risk of 3-5% not significant 
reduction of CDI with probiotics (p 
=0.70)  
-Baseline risk > 5% significant risk 
reduction with use of probiotics: RR = 
.30 (risk reduction of 70%), 95% CI 





for analysis of 
adverse events 













-Setting has a 
few countries 
that may be 
considered not 

























is 3%  
I 
Note. LOE = level of evidence, RCT = randomized control trial, N = total sample population, CDAD = Clostridium difficile infection, RR = relative risk, 






































experience of in 
hospital 
treatment of 
CDI. The study 
aimed to assess 
the impact and 
burden of CDI 







-N = 24  
-n = 12 French 
patients (9 men, 
3 women). 
- Age range: 
41-91 years old.  
-Average 
hospital length 
of stay 30 days.  
-n = 12  
-USA patients 
(10 women and 
2 men). 
 Age range: 50-
78 years old.  
-Average length 
of stay 8 days.  
-All patients 
had CDI within 
the 14 months 











-Purposive and some 
convenience sampling used. 
(a research company found 
participants but a doctor at a 
single hospital also enrolled 
a few of his own patients).  
-Semi-structured interviews 
-Open ended questions used  
-4 researchers used (2 from 
each country)  
-Interviews conducted via 1-
hour phone call that was 
recorded  
-Interview guide was 
utilized by researchers  
-Data coding performed 
with Atlas.ti software.  
-Data saturation was 
predetermined to be when 
less than 5% of new 
concepts were emerging 
with each interview. Data 
saturation began to occur at 
15th patient interviewed. 
-Data was grouped into 
three stages: prior to 
hospitalization, during 
hospitalization, discharge  
-Negative effects seen in 
psychological and 
emotional health on patient 
and family 
-Subsequently patients 
reported change in diet and 
health habits post 
discharge and through time 
of interview  
-Negative effects on 
cognitive abilities 
(experienced pre and 
during hospitalization) 
-Negative effects on 
physical health, 
experienced throughout pre 
diagnosis, and post 
treatment  
-Negative effect on sleep 
seen during and post 
hospitalization 
-Negative effects on 
professional life 
experienced diagnosis, 




diagnosis, treatment and 
post treatment 
-Interesting article 






-Motivating on the 
precaution’s 
healthcare workers 
can take to prevent 
this infection.  
-Brings to light the 
other aspects of 
burden to CDI other 
than increased 





repercussions of the 
infection.  

































ques out for 
examination.  
VI 









































-25 studies included  
-Pooled N- 2242  
-Cancer patients receiving 
chemotherapy, radio 
therapy or surgery whom 





and any adverse events. 
-Setting- inpatient  
-Japan, Italy, Canada, 
Australia, Greece, China, 
Slovakia, Brazil, 
Thailand, Spain, Finland, 
India, Hungary. 
-1995-2018 
-Systematic review and meta-
analysis 
-Focused on obtaining RCTs, 
non-randomized studies and 
case reports were included in 
safety analysis.  
- Databases searched: 
Medline Embase, AMED. 
-Selection- 2 reviewers 1 
separate party for 
discrepancies  
-Cochrane risk of bias tool 
used to minimalize selection 
risk 
-Loke Method used to assess 
quality of studies  
-Data analyzed by Mantel-
Haenszel method  
- 16 studies used probiotics 
with >1 strain of bacteria, 11 
studies include >3 strains, 18 
studies included 
Lactobacillus strains, 15 
included Bifodobacterum  
-Outcomes assessed: 
antibiotic associated diarrhea, 
gastrointestinal infections 
and any adverse events 
-Pooled analysis- 
reduced incidence of 
AAD: OR=0 .52, 95% 
CI = [0.34-0.78] 
-Results concerning 
severe diarrhea, 
septicemia, and central 
line infections had poor 
confidence intervals due 
to high heterogeneity 
reported in studies 
-Severe diarrhea: OR = 
0.67, 95% CI = [0.15-
2.98] 
-Septicemia: OR = 0.39 
95% CI = [0.13-1.17] 
-Adverse events in 
intervention group = 237 
Adverse events in 
control group = 314 
-Author states no 
conclusions of probiotic 
efficacy nor safety can 
be determined due to the 
vast heterogeneity 





and strain of 
probiotic not 





bias high 29% 
-Author 

































Table D7.  






























and safety of 
probiotics 
(any strain or 
dose), for the 
prevention 





-N = 3,818 adult or 
pediatric  
patients in randomized 
control trials treated 
with antibiotics and 
received probiotics of 
any strain or dosage 
that were tested for 
CDI/stool analysis  
-Duration of patient 
follow up ranged from 
1 week to 3 months 
-Study’s initiation and 
duration of probiotic 
treatment varied 
-Setting: Inpatient and 
outpatient. 
-Date of studies ranged 
from 1989-2010 
-Sample size was not 
large enough to meet 
power. Needed 5,676 
samples, only obtained 
3,818 
-Systematic Review 










- Each individual 
article was assessed 
for quality using 
GRADE approach 
- 20 RCTs were 
included in analysis.  
-Used relative risks 
and 95% CI, used 
alpha of (0.05) and 
Beta of (.20) with a 
relative risk 






-Risk bias was low in 7 studies 
and high/unclear in 13 studies 
- Overall quality of evidence 
moderate. Baseline risk of CDI 
ranged from 0-40%  
- Findings: patients receiving 
probiotics showed risk reduction. 
RR = 0 .34, 95% CI = [0.24-
0.49], Chi squared = 0%, and 
heterogeneity = (p = 0.79) bias 
low. 
-  Control risk = 50 cases per 
1000 persons 
- Intervention group 17 cases per 
1000 persons 95% CI [12-25]  
-Writer notes effect size for CDI 
reduction is moderate but no 
statistics are given  
- Studies using multiple species 
probiotic versus single strain 
showed relative risk reduction of 
CDI however not statistically 
significant 
Multi-strain: RR= 0.25, 95% CI 
= [0.15-.41]  
Single species: RR = 0.50, 95% 
CI [0.29-0.84] 
-Date of literature 
reviewed 
included studies > 
10 years old  
-  Low 
heterogeneity 
between studies is 
good.  
-Too small of 
sample size / high 
risk of type 2 










-13 of the 20 
studies data for 
CDAD were 
missing for 5-























of probiotics  
 
I 
Note. LOE = level of evidence, CDAD = Clostridium difficile-associated diarrhea, CDI = Clostridium difficile infection, RCT = randomized control 
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study findings  
 to estimate the 
direct medical 
costs that might 
result from the 




formula in two 
different doses to 
reduce the risk of 












N = 255  
-Placebo: n = 
84, cohort 1 
(one capsule 
dosage): n = 
85, cohort 2 
(two capsule 
dosage): n = 
86 
- Study data 
obtained from 






years of age, 
hospitalized 




within 36 hours of antibiotic  
-Cost were determined 
based on the 2009 United 
states dollar, using the 
Consumer Price Index. 
-Only direct costs 
determined- no adjusts for 
quality of life 
-Hospital costs determined 
by the median cost of 
hospitalization in relation to 
diagnosis of CDI which was 
obtained from a USA study 
in 2009 
-Authors utilize a decision 
tree to formulate 5 
assumption models. 
-Utilized Crystal Ball 
software for all the analysis 
data 
Study found decreased 
incidence of CDI with 
probiotics versus placebo: 
Placebo= 23.8%, Cohort 
1= 9.4%, Cohort 2 = 1.2% 
-Cost of CDI related 
hospitalization per patient, 
per day= 1,424.16 
- Findings supported cost 
effectiveness of probiotics:  
-Due to reduced risk 
reduction and reduced 
incidence of CDI, by 
implementing dosage of 1 
probiotic per day for all 
patients at risk, results in a 
savings of 981 dollars per 
patient.  
-Implementing dosage of 2 
probiotics per day results 
in savings of 833/patient. 
-For a hospital comparable 
to the one in the Gao 
study, this results in 
1.68million dollars savings 




















hospitals do.  
Must keep in 
mind, these 
figures are 
based off of 
values from one 
study. 
However, it is 
beneficial to see 
the cost savings 
that occurs 
when few cases 
of CDI are 
prevented.  
I 
Note.  LOE = level of evidence, AAD = antibiotic associated diarrhea, CDI = Clostridium difficile, N = total sample population, n = sub-sample 
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before the start 
of routine 
administration 



















ward at a medical 
university in 
Silesia, Poland.  
-Data analyzed for 
2 years  
-October 2012- 
October 2013 















-In the period between 
2012-2013 the unit’s 
routine was to 
administer probiotics of 
any variation to reduce 
incidence of CDI 
-2013-2014 LP299V 
was the only probiotic 
administered 
concurrently with the 
start of any antibiotic 
-CDI diagnosis made 
by 2 step 
immunoassays. Any 
patient with diarrhea 
was tested.  
-Statistical analysis 
performed by 
STATISTICA 7.0  




incidence of CDI 
post intervention 
from 1.21% to 
0.11%, p = 0.0001 
-Total analysis of 
both groups 
identified urinary 
tract infection was 
the main diagnosis 
and reason for 
treatment with 
antibiotics which 
























but unclear if 
staff was blinded 
or knew study 
was being 
performed  
-Total amount of 
patients who had 
CDI was low- 
24/3533  
-Power for study 
was not specified 
-In the intervention 
time frame, less 
antibiotics were 
prescribed. Thus, 
results may be skewed 
due to less high-risk 
antibiotics being used. 
-PPI use was noted in 
86% of patients who 
had CDI. In the 
intervention group less 
patients took PPIs 
-This patient 
population is 
considered a higher 
risk patient population; 
these findings may 
support that probiotics 






























































antibiotics.   
 
26 RCTs   
N = 7,957  
Received 
probiotics: n = 
4,124,  
No intervention: n 
= 3,833   
-Inclusion: RCT 
comparing the use 




instituted within 3 
days of antibiotic 
start, and 
continued for the 
entire duration of 
the antibiotic 
treatment.    
Exclusion: most 
studies excluded 
patients that were 
severely 
immunocompromis
ed, and who had 
gastrointestinal 
surgery.  
-Systematic Review and 
Meta-Analysis   
-Comprehensive Meta-
Analysis software 
version 3.  
-Cochrane’s Q and I²    
to assess study 
heterogeneity   
-Two tailed T-test used 
for data sets.   
-Sub-group analysis 
performed on type of 
probiotic used, age, and 
patient setting (inpatient 
vs outpatient) 
-Funnel plot utilized to 
rule out selection bias.  
-Search engines used: 
PubMed, Cochrane, and 
Google Scholar  
-Diagnosis of CDI made 
by presence of diarrhea 
and positive stool 
culture  
-Measured CDI rates, 
patient length of stay, 
patient age, and hospital 
versus outpatient setting 
-No publication bias 
present: Eggers test 
(p = 0.748) 
-No significant 
heterogeneity 
between trails (p = 
0.751). 
-Probiotic group had 
significant 
decreased risk in 
developing CDI: 
RR= 0.63, 95% CI = 
[0.294-0.531], p = 
0.001 
-Hospitalized 
patients were likely 




-Inpatient: (RR = 
0.390, 95% CI 
[0.283-0.538], p = 
0.001) -Outpatients 
(RR = 0.306, 95% 
CI [0.013-7.470], p 
= 0.468) 
- Flaw is that the 
review includes 
seven studies that 
were greater than 10 
years old.  
- Limitations in 
differences in strain, 
dosage, and 
duration of 
probiotics used.  
-Heterogeneity 





range- inpatient and 
outpatient included 
as well as adults 
versus children.  
- no mention on 
how studies were 
measured for quality 
or how many 
reviewers were 
included. 
- Overall thorough 
meta-analysis  
- Many of the studies 
included in the 
analysis do not note 
the side effects of 
probiotics. However, 
four studies did 
report no significant 
difference in side 
effects from probiotic 
group to placebo.  
- Supports the use of 
probiotics  
-Author addresses 
there are a few case 
reports noting sepsis 
believed to be related 
to probiotic use. 
They discern this 
evidence as being 




Note. LOE = level of evidence, CDI = Clostridium difficile infection, RCT = randomized control trial, N = total population sample, n = sub-population 








































risk of CDI 







course of 30 
days.   
 















and received an 
intervention of 






probiotics for at 




 -Data from Cochrane 
review was utilized to form 
a cost analysis. 
-Relative risk rates of CDI 
and increased length of 
hospital stay was derived 
from systematic reviews  
-Length of treatment for 
CDI, length of probiotics, 
cost for stool analysis, 
special room cleaning, 
additional supply cost, and 
contact precaution costs all 
included in analysis and 
obtained from Alberta 
Health Services records 
(public funded healthcare 
system).  
- Cost per day of contact 
precautions was used from 
a study performed in 2012. 
-Utilized 1-way sensitivity 
analysis for assessing cost 
savings per relative risk 
rates.  
- Did not directly assess 
quality of life indicators 
into cost versus savings 
-Reduced risk of CDI in intervention 
group 5.05% versus 2%  
- Cost of probiotics per patient if 
administered during course of antibiotic 
therapy and 5 days post completion = 24 
dollars.  
- Cost per patient treated for CDI if 
relative risk is 5% in intervention group 
= 327 dollars versus non-intervention 
group = 845 dollars. Cost savings of 518 
dollars per patient. 
-Cost savings per patient if relative risk 
is 1% (low) is 73 dollars per patient 
treated. 
- Cost savings per patient if relative risk 
is 25% (high) is 3,098 dollars per treated 
patient 
- Writer expresses the high likelihood of 
increased patient satisfaction/ quality of 
life with reduced risk of CDI with the 
probiotic intervention due to reduced 
risk for lengthened hospital stay, the 
emotions related to being in isolation, 
and the physical complications that arise 
from CDI (p.1082). 
-Theoretically for a hospital with 
380,000 admissions the cost for 
probiotics would be 2.2 million dollars 
but may result in a 44-million-dollar 
savings (p. 1085). 
-On average 
patients with 
CDI spend 1-3 
weeks longer 















for CDI is 
about 3%  




































Table D12.  

















































difficile rates.   
-N = 43,206  
-Cohort one: n = 
21,166  
-Cohort two: n = 
22040   
-Cohort/phase 
one:   
July 1st 2013-
June 30th 2014   
-Cohort two:   
July 1st 2014-
June 30th 2015  
-Exclusion- Age 








care unit patients.  
-Setting: Johnson 
City Medical 
Center (488 bed 
institution)   
-Single center retrospective 
cohort study   
All patients admitted to 
hospital included in study. 
Standard infection control 
measures maintained for all 
patients.   
-Methods: during phase one, 
physicians were educated 
on risks of PPI prescribing 
in relation to increased CDI 
rates. -A probiotic bundle 
was included in order sets 
for all patients receiving 
antibiotics   
Florajen was ordered as a 
once per day dosage.   
-Hospital associated CDI 
was defined as diagnosis 
after 3 days since admission 
and diagnosis was made 
using a polymerase chain 
reaction test Cohort 
comparison tests were made 
using a Mann-Whitney test. 
To analyze a cohort’s 
impact on CDI rates a 
Fischer’s exact test with an 
alpha of 0.05 was used.   
-Statistically 
significantly decreases 
from cohort one to 
cohort two: PPI usage- 
677 to 581, (p = 0.0002). 
Health care associated 
CDI rates (number of 
CDI rates per 1000 
patient days) 0 .49 to 
0.39 (p = 0.04). This 
represents a relative risk 
reduction of 20%  
-Probiotic usage 
increased significantly 
from cohort one to 
cohort two: 97 to 223 (p 
= 0.0006.)  
-Cost savings: the 
average additional costs 
associated with hospital 
acquired CDI for this 
institution is 11,000 
dollars per patient. A 
reduction in 12 cases 
over the year (which was 
seen in this study), 
results in a savings to the 
institution of 130,000 
dollars per year. 
-Flaw is that the 
study does not 
include 
randomization and 




be truly determined 
due to additional 
variable of reduced 
prescribing of PPIs  
-  Overall, good 
quality of a small 
institutional 
change Adding 
probiotics to an 
antibiotic 
prescribing order 
set is a good 
method to increase 
usage. This also 
allows prescriber 
autonomy as they 
can elect to not use 


















capsule route. If 















Note. LOE = level of evidence, N = total sample population, n = sub-sample population, PPI = proton pump inhibitor, CDI = Clostridium difficile 




































Cost analysis to 
assess the benefits 
financially for the 
institution and also 
assessing quality of 
life via length of 
hospital stay in 
relation to the use of 
prophylactic 
probiotics for the 
prevention of 
Clostridium difficile 
in adolescents and 
children.  




being incidence of 
CDI and direct 
medical costs 
related to treatment 
of the incidences of 
CDI.  
-Hospitalized 
patients less than 18 
years of age 
receiving antibiotics 
intravenously or 
orally and probiotics  
-The 4 studies were 
not described in 










- 2 independent 
reviewers assessed 
literature. Cochrane 
handbook was used 
to prevent selection 
bias 
- Cost analysis was 
based off of United 
States hospital costs.  
- Univariate 
sensitivity analysis 
was used along with 
a decision tree model 
to analyze data  
- Oral probiotics lowered 
risk of CDI 4.6% to 
0.45%. No confidence 
interval or p value given.  
- Cost of probiotics per 
day averaged 2.83 
dollars.  
- For institution with the 
probiotic strategy total 
cost per patient treated 
for was 16,668.70 
dollars compared to 
20,355 dollars per 
patient treated in the 
non- intervention 
hospital due to risk 
reduction  
- Cost savings of 3,686 
dollars per patient 
treated.  
- No data on selection 
bias/ heterogeneity of 


























appear to reduce 
incidence of 
CDI and have 






review due to 
lack of detail 
and  
I 


































effect of adding a 
probiotic called 
Bio-K+ (Lacto 
acidophilus and L. 
















outcome to be 




severity of CDI 
symptoms  
-N- 31,832   
-Phase one: n = 
1,580  
-Phase two and 
three: n = 4,968  




January 2004  
-Phase two: 
February and 
March 2004  






Quebec, Canada.   
-Inclusion 
criteria: age >18 




experimental cohort study  
-Methods- Probiotic 
administered within 2-12 
hours of any antibiotic. 
Probiotic continued for 30 
days or until antibiotic 
completion. 
-Consisted of four phases:   
1- Standard precautions    
2. Implementation of liquid 
probiotic for all patients on 
antibiotics   
3. Hospital relocated/new 
built hospital  
4. Data comparison with 
regional hospitals near 
Quebec  
-Instruments- SPSS data 
analysis   
Measures: level of 
significance, alpha- 0.05  
Incidence rates between 
phases compared with 2-
sided chi-square tests and 
student’s T- tests  
-Phase 1: Mean of 18.4 
cases per 1000.   
5.1 severe cases per 1000 
people.   
-Phase 2: Severe cases of 
CDI decreased from 5.1 
cases per 1000 to 1.3 cases 
per 1000, (p = 0.03).   
-Phase 3: Cases of CDI 
dropped from Phase one 
mean of 18.4/1000 to 
3.8/1000. (p = 0.003).  
-Severe cases decreased 
from 5.1/1000 patient to 
0.21/1000 patients (p = 
0.001)  
When comparing phase 1 
with phase 2 and 3 
combined, (pre-
intervention with post 
intervention), rates of CDI 
decreased 73% (p = 0.001)   
Severe cases of CDI rates 
decreased 27.5% (p = 
0.001)   
-No adverse events found 






















two groups.   
-Study was of 










review board.  





outside of the 
USA. 























Literature Review  
Note. LOE = level of evidence CDI = Clostridium difficile infection, AAD = antibiotic associated diarrhea, RCT = randomized control trials, H. pylori = 

















































-16 studies included 
focusing on hospitalized 
adults receiving 
antibiotics and probiotics 




and or Enterococcus with 
the end point assessing 
CDI, and/or AAD rates,  
-Inclusion: studies in 
English, designed as 
RCTs.  
-Exclusion: probiotics 
used for reoccurring CDI 
treatment of H.pylori. 
-Only 5/16 studies were 
multicenter 
- Studies were conducted 
in USA, UK, China, 
Canada, Italy, Norway, 
Turkey, and Switzerland.  
-Mean ages: 33-79.9 
 
-Systematic Review & Meta-
Analysis 
Search engines used: Medline, 
Embase, Cochrane. 
-3 reviewers analyzed each 
article to limit inclusion bias 
-Each article was reviewed by 
2 independent reviewers using 
the global quality rating scale 
(good, fair, or poor). 
Disagreement on an article 
was resolved by 3rd reviewer. 
-Data synthesis tool used for 
meta-analysis: RevMan 5.0 a 
Cochrane collaboration tool.  
- RR, RD, NNT, & 95% CI, 
calculated by DerSimonian 
Laird Method.  
-Clinical heterogeneity was 
assessed for population type, 
probiotic type, and quality of 
study.  
-Funnel plot used to assess for 
publication bias. 
 
-Rates of CDI = 3% 
or 18/572 
intervention and 
55/527 in placebo 
yielding a RR = 
0.37, 95% CI [0.22-
0.61], RD = 0.07, 
95% CI [0.11-.0.02]. 
NNT 14, 95% CI [9-
50] 
-Meta analysis of 
type of probiotic in 
relation to reduction 
of rates of AAD and 
CDI all showed 
reduction. However, 
only the combined 
Lactobacillus 
probiotics showed a 
significant reduction 
in CDI & AAD. 





























CDI, (4, 95% 
CI [9-50]), is a 
large CI this is 
concerning as 
cost vs benefit 
may not be 
there if NNT 












reduce risk of 
CDI and AAD  
I 






















































- N = 1530 
-Control: n = 756 
-Treatment: n = 
group- 774 
























-Systematic Review with Meta-
analysis  
Data collected from 17 different 
search engines. A 40-step search 
strategy was performed using 
Medline, Embase, and Amed 
Data collection took place from 
2010- 2012.  
-2 independent reviewers for 
study selection, 1 separate 
review used for disputes.  
Studies were reviewed utilizing 
Cochrane collaboration risk for 
bias assessment tool  
-Data analyzed using Rev Man 
5.2 system.  
-Variables- decreased incidence 
of diarrhea utilizing the common 
toxicity criteria for analyzing 
degree and severity of diarrhea 
and adverse outcomes  
 
Clinical heterogeneity was 
assessed for selection criteria, 
performance, detection bias, 
attrition bias, and reporting bias.  
Bias detected by I² > 50%  
-Efficacy: probiotics may be 
beneficial in reducing frequency 
of diarrhea: OR = 0.32, 95% CI 
[0.13-0.79] p = 0 .01 
-Data to support probiotics may 
reduce frequency of bowel 
movements appears promising, 
however only two studies were 
included in this analysis and bias 
was high in studies. Therefore, 
full conclusions cannot be drawn 
(mean bowel movements per day 
decreased by 9.6 movements, 
95% CI [10.45- 8.75], p = 
0.00001 
-Safety: pooled adverse events 
in probiotics = 103 versus 
placebo =145 
-No statistical analysis for 
significance noted for adverse 
events. 
-Author note: due to the 
significant heterogeneity of 
treatment options and variation 
of standard of cares and 
numerous variables, determining 
which adverse effects are related 
to probiotic consumption is 
fairly impossible 
-Study does 
not provide in 
depth pooled 
demographics 




for safety  
 -Effect size 















-Article seems to 
support use of 
probiotics and 
infers that cancer 
patients are 
immunocompro
mised and likely 
to have the 
highest risk of 
adverse events, 
yet appear to not 




-The authors do 
describe the case 




events. In some 
cases, the 
adverse events 
are proven to not 
be related to 




Note.  LOE = level of evidence, RCT = randomized control trial, N = total sample population, n = sub sample population, OR = odds ratio, CI = 







Table D17  
Literature Review  































Evaluate the safety of 
Lactobacillus 
rhamnosus probiotic 
as a treatment method 
in the pediatric patient 
population who are 
experiencing graft 
versus host disease 
(GVHD) and/or who 
have recently 
undergone HSCT 
many of whom have 
CDI or other GI 
ailments. The aim 
specifically was to 
assess for probiotic 
associated bacteremia.  
N = 15 



















varied from one 
capsule or 








analysis of what 
immunosuppres
sive medicine 
the patients are 
on. occurrence 
rates of GVHD 





within the first 
100 days of 
transplant. None 
of these cases 
occurred while a 
patient was on the 
Lactobacillus 
rhamnoses 
probiotic. None of 
the 5 cases of 
bacteremia were 
related to the 
Lactobacillus 
species.  
70% of the 
patients had CDI 
or GI GVHD by 








in the population 
characteristics 
-No rigor in 
study due to 
prospective 
nature.  
- Low power as 
only had 15 
patients  
-Fair study. Most 
shows the safety 










This study does 
not analyze the 
efficacy of 















Literature Review  
Note. LOE = level of evidence, CDI = Clostridium difficile infection, N = total sample population, ICU = intensive care unit, RCT = randomized control 






















et al.   
(2013) 
CINAHL 





















reduces the risk 
of CDI and 
antibiotic 
associated 
diarrhea as well 
as analyze 
adverse events   
-N = 122  
-Placebo: n = 61 





severe nausea and 
vomiting, no oral 
access, ICU 
admission, had 
diarrhea prior to 
study initiation, acute 
pancreatitis, previous 
use of probiotics 1 
week before study 
initiation, severely 
immunocompromised










-RCT (stated in article) reviewer feels 
it is Quasi- experimental due to 
sampling technique 
-Double Blind 
-Stratified cluster sampling used 
-Patients were assessed for eligibility, 
if consent approved, were 
administered probiotic or placebo 
within 48 hours of first antibiotic. 
-Probiotic and placebo administered 
twice per day for the duration of 
antibiotic treatment and 7 days after. 
-Patient diary: reported if medication 
was taken, symptoms, number of 
stools, and stool characteristics. 
-Daily Bristol stool charts. If stool was 
categorized as type 6 or 7 twice in one 
day, a stool sample was sent for CDI 
testing.  
-CDI testing performed using Premier 
Toxin A+B at Hull and Bristol site. 
Quick Check complete test was used 
at Weston and Wigan sites 
- 
-No determination 
could be made on 
reduction of CDI 
rates as neither 
group had an 
incidence of CDI.  
-Significant 
reduction of AAD 
was noted (p = 
0.006) 
-There was no 
significant 
difference in length 
of hospital stay. 
- Adverse side 
effects were not 
significant between 
the control and 
interventional 
group (p = 0.63)   
In fact, the placebo 
group had higher 
rate of side effects 





-Low N, Power 
analysis for 90%, 
5% LOS, N 




N = 231. end 
point- N = 122. 
- Poor retention  
-Study used two 
different 
instruments 
depending on site 
to test stool 
samples for CDI. 






sed patient not 
defined.  


















































































-19 RCTs analyzed 
-Total sample: N = 6,261  
-Probiotic: n = 3,277 
-Placebo: n = 2,984 
-Mean age: 68 
-Inclusion criteria: 
hospitalized patients, age 18 
years or older on antibiotics 
IV or oral, receiving 
probiotics as a primary 
prevention method. 
-Excluded patients: 
pregnant, neutropenia, HIV, 
malignant cancer, transplant 
patients receiving 
immunosuppression, and 
preexisting GI disorders. 
-Probiotics used in studies= 




Streptococcus either alone 
or in combination. 
-Studies conducted in 8 
countries: USA, UK, 
Turkey, Canada, Norway, 
Italy, China, & Germany. 
-Systematic review 
& meta- analysis  
-Search engines: 
Medline, Cochrane 




settled by 3rd 
reviewer.   
- Bias controlled by 








- Publication bias 
was assessed by 





STATA program  
-No significant heterogeneity across 
the 19 studies (p = 0.56) 
-Meta- analysis supports probiotic to 
prevent CDI vs placebo or no 
intervention  
Risk of CDI in control group: 0-40%  
Risk of CDI in intervention group: 0-
11%  
RR= 0.42, 95% CI [ 0.30-0.57] p = 
0.001 
-NNT= 43, 95% CI [36-58] 
- Probiotic initiation: more effective 
if started within 2 days of antibiotic 
administration: RR = 0.32, 95% CI 
[0.22-.48] versus greater than 2 days 
from antibiotic start time: RR = 0.70, 
95% CI [0.40-1.23] 
- No significant difference in 
probiotic formulation  
effectiveness (p = 0.34)  
-Writer does argue use of 
Lactobacillus due to heavily studied 
formula  
-Analysis of adverse effects from 
placebo to intervention not 
statistically different (p = 0.35) 
-Quality of evidence measured by 
GRADE system = high quality 



















suggests 1 case 
of CDI would 
be prevented 
by every 23-















Note. LOE = level of evidence, CDI = Clostridium difficile, RCTs = randomized control trials, USA = United States of America, UK = United Kingdom, IV = 









Theme Matrix  
Item Methods/backgrounds Interventional Methodology Findings 
 Heterogeneity/Selection 




















Box et al. 
(2018) 
Y NS Y NS N NS NS 
Carvour et al. 
(2019) 
Y NS NS NS N  NS NS 
Dudzicz et al. 
(2018) 
Y N Y Y Y Y NS 
Goldenberg et 
al. (2018)  
N-rates of CDI  
Y-Safety 
NS Y NS Y NS Y,   
Guillemin et 
al. (2014) 
Y N/A N/A N/A N/A N/A N/A 
Hassan et al. 
(2018) 
Y N NS NS N/A Y Y 
Johnston et al. 
(2012) 
N NS Y  NS Y NS Y  
Kamdeu Fansi 
et al. (2012) 





Y N Y Y Y NS Y 
Lau et al. 
(2016) 








Table E1. (continued) 
Theme Matrix  
Item Methods/backgrounds Interventional Methodology Findings 
 Heterogeneity/Selection 



















Leal et al. 
(2016) 
Y NS Y NS Y Y NS 
Lewis et al.  
(2017) 
Y Y Y Y Y Y NS 
Li et al. 
(2018) 
Y NS Y NS Y Y NS 
Mazaide et al. 
(2013) 
Y N Y Y Y NS Y  
Pattani et al. 
(2013) 
Y Y Y NS Y NS NS 
Reman et al. 
(2014) 
Y N Y NS NS NS Y  
Sadanand et 
al. (2019)  
Y N Y NS NS NS Y  
Selinger et al. 
(2013) 
Y Y Y NS NS N NS 
Shen et al. 
(2017) 
N Y Y Y Y Y NS 






















three days of 
antibiotic start. 
-Continued for the 













-12/16 studies report 
reduced incidence of CDI  
 
-Cost effective/ substantial 
cost savings to institutions  
 
-  No major differences in 
side effects from probiotic 
intervention. One study 
reported significantly less 
adverse events in probiotic 
group than placebo/control  
versus placebo/control 
group.  
Ranged from systematic reviews 
with meta-analysis to small case 
cohort quasi-experimental 
studies.  
Note. CDI = Clostridium difficile infection
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